MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Lificiguat

CAS No. : 170632-47-0

MCE 站：Lificiguat

产品活性：Lificiguat 结合到 可溶性鸟苷酸环化酶(sGC)的β亚基，在CO存在条件下，K_d 为 0.6-1.1 μM。

研究领域：GPCR/G Protein

作用靶点：Guanylate Cyclase

In Vitro: Soluble guanylate cyclase (sGC) is a heterodimeric heme protein ａnd the primary NO receptor. Lificiguat (YC-1) binds near or directly to the heme-containing domain of the beta subunit. In the absence of CO, Lificiguat (YC-1) binds with K_d=9-21 μM, depending on construct. In the presence of CO, these values decrease to 0.6-1.1 μM. Lificiguat (YC-1) greatly enhanced CO binding to heterodimeric sGC, as expected (K_d=1 μM). Lificiguat (YC-1) stimulates sGC two- to four-fold in the absence of NO but acts synergistically with CO or NO to achieve several hundred fold activation. Binding of Lificiguat(YC-1) can also overcome inhibitory phosphorylation of sGC. Lificiguat (YC-1) is a soluble guanylyl cyclase (sGC) activator. HCC cell lines HepG2, BEL-7402 ａnd HCCLM3 are incubated for 72 h with Sorafenib and/or Lificiguat (YC-1). Sorafenib or Lificiguat (YC-1) alone inhibits HCC cell proliferation in a dose-dependent manner. Moreover, combination of Sorafenib ａnd Lificiguat (YC-1) significantly suppresses proliferation of HCC cells in a dose-dependent manner. In addition, at the ED₅₀ doses for both Sorafenib ａnd Lificiguat (YC-1), combination index values (CI)=0.93 in HepG2, 0.95 in BEL-7402 ａnd 0.72 in HCCLM3 respectively, suggesting that Sorafenib ａnd Lificiguat (YC-1) synergistically inhibit proliferation of HCC cells.

In Vivo: Lificiguat (YC-1) (30 or 60 mg/kg, i.p.) inhibits MDA-MB-468 tumor growth in a dose-dependent manner. The effect of the prodrug formulation of Lificiguat (YC-1), YC-1-S, in MDA-MB-468 tumor-bearing mice is also investigated. In vivo pharmacokinetic analysis reveal that YC-1-S is quickly converted into its active form. Mice are administered 20, 40 or 80 mg/kg YC-1-S p.o. YC-1-S also displays dose-dependent inhibition of MDA-MB468 tumor growth. Both Lificiguat (YC-1) ａnd YC-1-S dose-dependently reduce tumor weight. Moreover, the mean body weight of mice is not affected by Lificiguat (YC-1) or YC-1-S compare with vehicle-treated groups. Lificiguat (YC-1) is a potent NO-GC activator reported to improve rodent learning behavior when examined with the Morris water maze (MWM) ａnd avoidance tests. Lificiguat (YC-1) enhances long-term potentiation (LTP) in hippocampal Schafer collateral-CA1 synapse via the NO-cGMP-PKG-dependent pathway ａnd potentiated LTP induction in the amygdala, increases the activation of ERK, ａnd potentiated the expression of brain-derived neurotrophic factor (BDNF) cAMP response element-binding protein (CREB) in response to fear memory test.

相关产品：Bioactive Compound Library Plus  |  GPCR/G Protein Compound Library  |  Anti-Cancer Compound Library  |  Vericiguat  |  Linaclotide  |  Methylene Blue  |  Riociguat  |  Cinaciguat  |  BAY 41-2272  |  NS-2028  |  Nelociguat  |  ODQ  |  Praliciguat  |  Olinciguat  |  Plecanatide  |  Guanylin(human) TFA  |  Guanylate cyclase-IN-1  |  (Rac)-BI 703704  |  (Rac)-MGV354  |  Ataciguat  |  BAY 41-8543  |  BAY 60-2770  |  MM 419447  |  (4-Acetamidocyclohexyl) nitrate  |  Runcaciguat

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。